Clinical Trials Directory

We are doing this study to find out if an experimental CAR-T cell therapy called MB-CART2019.1 (the study drug) may help eliminate cancer cells in patients who have relapsed or refractory DLBCL. The study drug will be combined with fludarabine and cyclophosphamide, which are both standard drugs used to treat DLBCL.

We are doing this study to look at blood, tumor, and lymph node tissue from people with melanoma so we can improve diagnostic methods and therapies for people with melanoma.

We are doing this study to collect information about an experimental test that is done during melanoma biopsies. Using this test, we may identify melanoma in the lymph nodes that is at a lower risk of being found in patients.

We are doing this study to find out if an experimental drug called MEM-288 (the study drug) is a safe and effective treatment for your cancer.

If you choose to join this study, you will:
- Be assigned to take the study drug, pembrolizumab, in combination with lenvatinib, or MK-7684, or carboplatin + etoposide
- Have blood draws
- Give urine samples
- Have imaging scans (CT and/or MRI)

Pembrolizumab, MK-7684, etoposide, and carboplatin are all drugs taken intravenously (through a needle in a vein in your arm). Lenvatinib is a pill that you take by mouth.

We are doing this study to see how tucatinib, trastuzumab, and mFOLFOX6 work to treat cancer of your colon or rectum that is HER2 positive with mFOLFOX6 alone or combined with bevacizumab.

We are doing this study to find out if the study intervention (additional delayed MRI sequences) can tell the difference between radiation damage and tumor recurrence.

We are doing this study to compare the effectiveness of atezolizumab + a multi-kinase inhibitor (either cabozantinib or lenvatinib) versus a multi-kinase inhibitor alone.